Tear film osmolarity measurements can diagnose dry eye disease

Article

Measuring tear film osmolarity is very effective in diagnosing dry eye disease.

Measuring tear film osmolarity is very effective in diagnosing dry eye disease, according to a paper published in Cornea.

The investigation led by Dr Christina Jacobi, Department of Ophthalmology, University of Erlangen-Nuremberg, Erlangen, Germany, involved 133 patients with moderate to severe keratoconjunctivitus sicca and 95 control participants. Each participant had tear samples taken directly from the inferior lateral tear meniscus. The TearLab osmometer was used to analyse tear film osmolarity.

The inclusion criteria was a Schirmer test with anaesthesia of less than 5 mm, a tear breakup time of less than 5 seconds and positive symptoms where the Ocular Surface Disease Index Score was over 83.

A tear film osmolarity of 320 mOsmol/L was found in the patients with moderate to severe keratoconjunctivitis. The control group presented with a tear film osmolarity of 301 mOsmol/L. Tear film osmolarity was significantly higher in patients with moderate to severe keratoconjunctivitus sicca compared to the control group. The study also confirmed that the official referent value in moderate to severe dry eye was approximately 316 mOsmol/L.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.